US approves Avastin for kidney cancer

4th August 2009, Comments 0 comments

Roche announces the Food and Drug Administration’s approval of Avastin to combat the most common form of kidney cancer.

Basel -- Medical authorities in the United States have approved the use of the drug Avastin to help combat the most common form of kidney cancer, the Swiss pharmaceutical giant Roche announced Monday.

Avastin has been approved by the Food and Drug Administration (FDA) to treat kidney cancer in combination with the drug Interferon Alpha, Roche said in a statement.

According to the results of the third phase of a clinical study, patients who used a combination of the two drugs lived nearly twice as long without their disease worsening compared to those who only used Interferon Alpha.

"This underscores our belief in the important clinical benefits that Avastin delivers as we push forward with our ongoing research programmes in more than 30 tumour types," said William Burns, chief executive of Roche's pharmaceuticals division.

Kidney cancer is the eighth most common type of cancer in the US, accounting for some 13,000 people in 2008.

Avastin has been available since the end of 2007 in Europe as a first line of treatment against advanced kidney cancer.

The news comes after the European Commission in late July approved Avastin as a treatment against breast cancer.

AFP / Expatica

0 Comments To This Article